Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-062919

Chief Executive Officer sold 20,000 shares at an average $142.29 ($2,845,782)

  • Chief Executive Officer acquired 20,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2020-12-10 Option exercise +20,000 $1.81 $36,200 189,189 D
Kulkarni Samarth Chief Executive Officer 2020-12-10 Sale −5,500 $141.17 $776,435 183,689 D
Kulkarni Samarth Chief Executive Officer 2020-12-10 Sale −5,034 $141.98 $714,727 178,655 D
Kulkarni Samarth Chief Executive Officer 2020-12-10 Sale −6,766 $142.75 $965,847 171,889 D
Kulkarni Samarth Chief Executive Officer 2020-12-10 Sale −2,100 $143.71 $301,791 169,789 D
Kulkarni Samarth Chief Executive Officer 2020-12-10 Sale −600 $144.97 $86,982 169,189 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2020-12-10 Option exercise · Stock Option (Right to Buy) −20,000 142,783 D
Open-market sales · 20,000 sh · avg $142.29 · $2,845,782
Loading xslF345X03/doc4.xml…